results

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

3 months ago

Silynxcom Announces First Half of 2025 Financial Results, Expands Client Diversity and Raised $2.9M to Support Growth

September 26, 2025 16:05 ET  | Source: Silynxcom Ltd. Netanya, Israel, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE…

3 months ago

Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025

September 26, 2025 16:04 ET  | Source: Maris-Tech Ltd. The company continues to advance AI-powered video streaming and edge computing…

3 months ago

Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage…

3 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) --…

3 months ago

Verano to Report Third Quarter 2025 Financial Results on October 29, 2025

CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a…

4 months ago

Euro NCAP to Launch New 2025 Assisted Driving Results

WhatLatest Euro NCAP AD results published online and via social media.WhenWednesday 24 September - 11:00 a.m. CEST.WhereGo to Euro NCAP's Press Releases or access videos…

4 months ago

Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00…

4 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

September 19, 2025 16:18 ET  | Source: MBX Biosciences, Inc. CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences,…

4 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

4 months ago